OrbiMed

Overview

OrbiMed is a healthcare investment firm founded in New York City in 1989[8]. The firm identifies and invests in medical and life sciences companies globally[4], seeking to invest in world-class healthcare companies to help drive innovation, address unmet medical needs, and improve patient outcomes[5]. OrbiMed manages roughly $20 billion under management[1] and invests across biopharmaceuticals, medical devices, digital health, diagnostics and healthcare services[1]. The firm operates 12 global offices[6], including its headquarters at 601 Lexington Avenue in New York[3], along with locations in San Francisco, Shanghai, Herzliya, Hong Kong and London[9]. OrbiMed's team comprises over 150 distinguished scientific, medical, investment, and other professionals[7]. The firm reports more than 500 portfolio companies and 130+ venture-backed IPOs[6], with notable portfolio companies including Insmed Incorporated and Avenzo Therapeutics[10].

The company's own site places it in New York: New York address listed first under 'Global Locations': 601 Lexington Avenue (at 53rd Street), 54th Floor New York, NY 10022-4629. Listed as. [3]

OrbiMed's investment business was founded in New York City in 1989. [8]

OrbiMed was founded in New York City in 1989 and has since added offices in San Francisco (2007), Shanghai (2007), Herzliya, Israel (2010), Hong Kong (2017) and London (2023). [9]

Business address: 601 Lexington Avenue, New York, New York, 10022. [12]

Growth & traction

OrbiMed reports $20 billion in assets under management across 12 global offices, more than 500 portfolio companies and 130+ venture-backed IPOs. [6]

OrbiMed describes "our team of over 150 distinguished scientific, medical, investment, and other professionals". [7]

Customers

OrbiMed highlights portfolio companies including ADARx Pharmaceuticals, Treeline Biosciences, Mirador Therapeutics, Insmed Incorporated, Avenzo Therapeutics and Perfuse Therapeutics. [10]